ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / MXCT
NRC (67) OABI (44) ONMD (26) ABSI (44) ⌘ Pro Terminal →

MaxCyte Inc. (MXCT) — RQD Stock Rating Cockpit

$1.45 -8.80% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.42

MaxCyte Inc. (MXCT) carries a Roarable Rating of E (Strong Sell) with 34/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $164.1M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on MXCT Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is MXCT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, MaxCyte Inc. (NASDAQ: MXCT) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 34/100 at a spot price of $1.45 (-8.80% 1D, market cap $164.1M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 14/20, SEC Balance-Sheet Forensics 5/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, MXCT ranks #630 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does MXCT compare to NRC and OABI in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Commercial Physical & Biological Resarch), MXCT carries a Roarable E (34/100 RQD), trailing P/E of N/A, gross margin of 96.0%, and ROIC of -27.1%. By comparison, NRC (NRC Health) holds a C+ grade (67/100 RQD, P/E 44.8x, ROIC 21.0%, cap $527.1M) and OABI (OmniAb Inc.) posts a D grade (44/100 RQD, P/E N/A, ROIC -22.6%, cap $742.9M). Among the 5-stock peer group, NRC leads on earnings multiple (44.8x) while NRC leads on capital efficiency (21.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for MXCT?
▼

Per MXCT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001287098), MaxCyte Inc. generated $21.0M in revenue (-5.7% YoY), -$44.6M in net income, and -$36.2M in free cash flow against $202.5M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $1.42 (-1.77%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 4/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (34/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-8.7% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • E
025507510034
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk E
Cash (4)Whales (14)SEC (5)Macro (8)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-11% Base Target
$2 Bull$1 Base$1 Bear
📬 FREE MXCT RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for MXCT)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (34/100 Composite)
🔍 WHY MXCT SCORES 34/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+14/20 pts (41% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▲ #2 Bullish Driver: Macro Regime Fit+8/20 pts (24% of score)

FRED Regime × Technicals: 70% of 52W Range • RSI-14 at 60.7 (BULLISH MOMENTUM)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
26
Grade E$0.96+49% Next Q
Q2 (-2Q)
29
Grade E$1.43+7.7% Next Q
Q3 (-1Q)
31
Grade E$1.54-5.8% Next Q
Current
34
Grade E$1.45-8.7% Hist 90D α
Trajectory: E (26) → E (34)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a MXCT Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While MXCT currently carries a cautious 34/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.27) and Max Pain ($1.52) forces dealer call-delta covering toward $1.89.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $MXCT• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “MXCT Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 34%NO 66%Trade / Inspect Odds →
RSI-14 MOMENTUMBULLISH MOMENTUM
60.730 Oversold · 70 Hot
ALTMAN-Z SHIELDDISTRESS RISK (<1.8)
1.52>3.0 Fortress Safe
PIOTROSKI F-SCOREWEAK QUALITY (1–4)
3 / 99-Pt Accounting
52-WEEK LASER RANGE70% OF RANGE
L: $1$1.45H: $2
1. Money & Cash Health● WEAK
Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: ERQD 4 / 20
2. Big Money & Insiders● TRIMMING
Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: D-RQD 17 / 40
3. Hidden Risks & Market Weather● WARNING
SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: ERQD 13 / 40
MULTI-MODEL JEV QUANT JURY DELIBERATION

3-of-3 JEV AI Jury Bearish Warning on MXCT

Cash & Moat Bull AI
ROIC & Free Cash Flow Model
BEARISH (20)

-27.1% ROIC with 96.0% gross margin and -20.26% FCF yield.

SEC Forensic Auditor AI
10-K Accruals & Altman-Z Guard
BEARISH (25)

Altman-Z 1.52 and Piotroski 3/9 pass balance-sheet audit.

Whale & Macro Hawk AI
Options Skew, 13F & Fed NetLiq
BEARISH (42)

17/40 institutional & smart-money positioning score with 8/20 macro alignment.

Bull Case: Why Buyers Like MXCT
  • ✓Established market leader in Health Care with deep daily trading liquidity.
Bear Case: What Could Go Wrong
  • !Company executives have done more routine share selling than personal cash buying lately.
  • !Sensitive to high interest rates and tighter Federal Reserve market liquidity.
  • !Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring MXCT)

  • ✓Walkthrough of MXCT's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
MXCT // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +68.60%📐 HORIZONTAL RANGE
2026-11-03O $1.73H $1.73L $1.45C $1.45VOL 963.8K
RES: $1.77SUP: $0.82SMA50: $1.27SMA200: $1.07
$1.83$1.54$1.26$0.98$0.69RES $1.77SUP $0.82$1.452026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

MXCT Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 MXCT Butterfly Map → + Track MXCT →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. -5.7% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on MXCT today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for MXCT. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for MXCT today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (MXCT)

Health Care Rank #630 of 1015 ⚔️ NRC vs MXCT Full Matrix →

1. Head-to-Head Health Care Peer Comparison (MXCT vs. NRC, OABI, ONMD, ABSI)

Industry: Biotechnology: Commercial Physical & Biological Resarch (12 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, MaxCyte Inc. (MXCT) ranks #630 by composite RQD confidence (34/100, grade E) and #596 by equity capitalization ($164.1M). Within this direct 5-issuer industry benchmark cohort, NRC leads on earnings valuation at 44.8x trailing P/E, while NRC leads on capital efficiency and profitability with 21.0% ROIC and — gross margin. NRC currently holds the highest overall quantitative score in the immediate peer group at 67/100 (C+) compared with MXCT at 34/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
MXCT ACTIVE
MaxCyte Inc.
E 34/100 — 96.0% -27.1% -8.80% $164.1M Benchmark Subject
NRC
NRC Health
C+ 67/100 44.8x — 21.0% +1.80% $527.1M /nrc-vs-mxct →
OABI
OmniAb Inc.
D 44/100 — — -22.6% -0.39% $742.9M /oabi-vs-mxct →
ONMD
OneMedNet Corp (Class A)
E 26/100 — -30.0% -35.0% +1.42% $25.4M /onmd-vs-mxct →
ABSI
Absci Corporation
D 44/100 — — -35.0% -12.94% $1.91B /absi-vs-mxct →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001287098 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), MaxCyte Inc. (MXCT) reported GAAP revenue of $21.0M (-5.7% vs. FY2024 revenue of $22.2M , and +7.5% cumulative change since FY2023) , GAAP net income of -$44.6M, operating cash flow of -$34.4M, and free cash flow of -$36.2M (-23.6% YoY). On the balance sheet, MXCT closed FY2025 with $202.5M in total assets against $0 in total debt (Altman Z-Score: 1.52, Piotroski F-Score: 3/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $21.0M -$44.6M -$34.4M -$36.2M $202.5M —
FY2024 (FY) 2024-12-31 $22.2M -$41.1M -$27.6M -$29.3M $239.5M —
FY2023 (FY) 2023-12-31 $19.5M -$37.9M -$21.7M -$21.7M — —

3. MXCT Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is MXCT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, MaxCyte Inc. (NASDAQ: MXCT) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 34/100 at a spot price of $1.45 (-8.80% 1D, market cap $164.1M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 14/20, SEC Balance-Sheet Forensics 5/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, MXCT ranks #630 in composite RQD confidence.

How does MXCT compare to NRC and OABI in the Health Care sector?

Within the Health Care sector (Biotechnology: Commercial Physical & Biological Resarch), MXCT carries a Roarable E (34/100 RQD), trailing P/E of N/A, gross margin of 96.0%, and ROIC of -27.1%. By comparison, NRC (NRC Health) holds a C+ grade (67/100 RQD, P/E 44.8x, ROIC 21.0%, cap $527.1M) and OABI (OmniAb Inc.) posts a D grade (44/100 RQD, P/E N/A, ROIC -22.6%, cap $742.9M). Among the 5-stock peer group, NRC leads on earnings multiple (44.8x) while NRC leads on capital efficiency (21.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for MXCT?

Per MXCT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001287098), MaxCyte Inc. generated $21.0M in revenue (-5.7% YoY), -$44.6M in net income, and -$36.2M in free cash flow against $202.5M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is MXCT trading relative to its 50-day, 200-day, and 52-week technical levels?

MXCT last traded at $1.45 (-8.80% on volume of 1,283,688 shares), positioning the stock +14.17% above its 50-day simple moving average ($1.27) and +35.51% above its 200-day simple moving average ($1.07). Across its 52-week range of $0.64 to $1.80, MXCT sits at the 69.8% percentile with a 14-day RSI of 60.7 (BULLISH MOMENTUM) and an implied next-earnings move of ±12.5% ($1.27 to $1.63).

Direct Sub-Reports: MXCT RQD Cockpit MXCT 12M Forecast MXCT Earnings & Move MXCT Dividends & DRIP MXCT Insiders & 13F MXCT Whale Options MXCT Profit Sankey MXCT News & Why
ROARABLE RATING BRIEF • RQD 34/100 (E) ✓ SEC XBRL & RQD VERIFIED

MXCT — MaxCyte Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

MaxCyte Inc. (MXCT) earns a live Roarable RQD composite score of 34/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $1.45 (-8.80% 1D, market capitalization $164.1M).

  • Fundamental Cash Engine (4/20): Anchored by return on invested capital (ROIC) of -27.1%, gross margin of 96.0%, operating margin of -60.0%, and free cash flow yield of -20.26%.
  • Whale 13F & Options Flow (14/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (8/20) + Forensic Balance Sheet (5/20): Incorporates a 1.00x equity beta, Altman Z-Score of 1.52, Piotroski F-Score of 3/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

MaxCyte Inc. Is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Commercial Physical & Biological Resarch industry. It has a market capitalization of $0.2B.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), MaxCyte Inc. (MXCT) reported $21.0M in annual revenue (up from $22.2M in FY2024, -5.7% YoY) and -$44.6M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($19.5M revenue, -$37.9M net income) through FY2025, MXCT scaled operating cash flow to -$34.4M and free cash flow to -$36.2M, backed by $202.5M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (E • RQD 34/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -20.26% and institutional whale pillar of 14/20. With Fundamental Cash Engine at 4/20 and Institutional Whale Flow at 14/20, sustained execution supports upside toward the upper end of the $0.64 – $1.80 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -60.0% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Biotechnology: Commercial Physical & Biological Resarch (Health Care), MXCT carries a macro regime beta of 1.00 and gross margin of 96.0%.

  • Key Question #1: Can MXCT sustain or expand its -60.0% operating margin and -27.1% ROIC against Biotechnology: Commercial Physical & Biological Resarch peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $21.0M and free cash flow of -$36.2M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is MXCT's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

MXCT Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for MaxCyte Inc. (MXCT) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to MXCT Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

MXCT Bull vs. Bear Conversation Board — What's Your Call at $1.45?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON MXCT 🐻 33% BEARISH CONVICTION
1. Pick Your Side on MXCT:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
DE DeepValue_CFA RQD DEBATE OPENER • Institutional Buy-Side 🐂 BULLISH 🎯 Target: $1.96 (+23.3%)
📌 Pinned Debate

Institutional accumulation (15/20 whale flow pillar) and a 96% gross margin indicate strong institutional interest and a high-margin re

The street is overcomplicating MaxCyte Inc. (MXCT). Institutional accumulation (15/20 whale flow pillar) and a 96% gross margin indicate strong institutional interest and a high-margin revenue base.. With an RQD score of 34/100 (E) and Forensic Balance Sheet at 5/20, any positive earnings surprise or guidance raise forces underweight funds to chase above $1.72.

RetailWhale_TX 🐂 BULL

Both sides have a point here — MXCT's 5/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.

FA FadeTheHype RQD DEBATE OPENER • Contrarian Tape Reader 🐻 BEARISH 🎯 Target: $1.37 (-13.8%)
Spot @ $1.59

Operating margin of -60% and FCF yield of -20.26% show the business is consuming cash, with Altman Z of 1.52 and Piotroski F of 3/9 sig

Careful chasing MXCT at $1.59. Operating margin of -60% and FCF yield of -20.26% show the business is consuming cash, with Altman Z of 1.52 and Piotroski F of 3/9 signaling a weak balance sheet.. Gross margin is 96.0%, but operating margin is -60.0%, which shows SG&A and reinvestment are eating into bottom-line EPS. Target $1.37 on multiple compression.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%